Periurethral calcifications identify higher urinary toxicity risk after prostate SBRT
Acute grade ≥2 urinary toxicity occurred in 64.7% of patients with periurethral calcifications versus 23.3% without them.
Acute grade ≥2 urinary toxicity occurred in 64.7% of patients with periurethral calcifications versus 23.3% without them.
In 30 endometrial cancer cases, RapidArc Dynamic improved pelvic OAR sparing and dose fall-off compared with VMAT, but required more monitor units.
After 26 Gy/5 with a 29 Gy simultaneous boost, five-year fibrosis was 8.9%, while breast pain was more frequent than without boost.
The 30-patient STEP-UP study will assess severe toxicity after dose-escalated SBRT, hyperfractionated reirradiation or chemoradiotherapy for unresectable rectal recurrence.
In 229 patients, late GI toxicity models achieved at best AUC 0.587, while GU prediction showed no reliable above-chance discrimination.
After 11.1% weight loss during oropharyngeal chemoradiotherapy, nasogastric tube placement and repeat CT simulation were completed on the same day.
A two-variable NTCP model predicted grade ≥2 acute esophageal toxicity with AUC 0.75 and was incorporated into Dutch proton selection criteria.
Median survival was 11 versus 8 months with WBRT plus simultaneous boost, but nonrandomized treatment selection limits causal interpretation.
After 70 Gy(RBE) in 28 fractions, ten-year biochemical control was 78.5%, with grade ≥3 GI and GU toxicity in 5.2% and 3.1%.
In 62 patients receiving focal salvage HDR brachytherapy up to 30 Gy, no acute grade 3 toxicity occurred; genomic risk stratification showed promise.
MR-only prostate SABR reduced median penile bulb dose from 4.6 to 2.2 Gy, with lower observed urinary and sexual toxicity in nonrandomized cohorts.
A model using 2,485 measurements predicted lymphocyte depletion with R² 0.65; reductions ≥75% were associated with poorer three-year progression-free survival.
After a second PSMA-guided metastasis-directed RT course, 50.2% of 177 oligorecurrent prostate cancer patients remained ADT-free at two years.
Across six European centers, CT-based stopping-power estimates varied by approximately 1% in soft tissue and up to 4.6% in compact bone.
Two weeks after proton FLASH, normal tongue tissue retained more triglycerides and showed distinct lipid-remodeling responses compared with conventional irradiation.